July 16, 2007
WEST SACRAMENTO, Calif., Jul. 16, 2007 - Lipomics Technologies, Inc., a privately held company that
specializes in clinical diagnostic development, announced today that it has entered into an agreement with
The University of California, San Diego. The collaboration will focus on clinical investigations aimed at
identifying mechanisms underlying the pathogenesis of non-insulin dependent diabetes mellitus (NIDDM),
obesity, and other disorders of insulin resistance. Studies are also in progress to identify the relative role of
each organ system (muscle, liver and fat) to the pathophysiology of NIDDM.
The company will collaborate on basic and clinical research programs from the lab of Jerrold Olefsky, MD,
Associate Dean for Scientific Affairs at the University. "I am very enthusiastic about this new collaboration
and think that the data generated through the Lipomics technology will help advance our scientific work."
"This collaboration is of special strategic interest to us as we continue to establish our clinical diagnostic
development programs. We are very pleased to be working with Dr. Olefsky and the University of
California, San Diego," said Meeta Patnaik, chief medical officer at Lipomics.
Lipomics will retain certain rights to develop diagnostic applications based on the data from the studies.
Lipomics seeks to partner with academic institutions and drug companies to advance its goal of developing
diagnostic tests for metabolic diseases.